ABIOMED (ABMD) Price Target Increased to $300.00 by Analysts at Leerink Swann

ABIOMED (NASDAQ:ABMD) had its price target lifted by investment analysts at Leerink Swann to $300.00 in a research report issued on Friday, The Fly reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Leerink Swann’s price target suggests a potential upside of 18.95% from the company’s previous close.

ABMD has been the subject of several other reports. Morgan Stanley upped their price target on shares of ABIOMED from $204.00 to $259.00 and gave the company an “equal weight” rating in a research report on Friday. Guggenheim reiterated a “buy” rating and set a $280.00 price objective on shares of ABIOMED in a research report on Friday. Jefferies Group reaffirmed a “buy” rating and issued a $300.00 price objective on shares of ABIOMED in a research note on Thursday. Piper Jaffray Companies reaffirmed a “positive” rating and issued a $300.00 price objective (up from $220.00) on shares of ABIOMED in a research note on Thursday. Finally, BidaskClub raised shares of ABIOMED from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 20th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. ABIOMED presently has an average rating of “Buy” and an average price target of $263.86.

Shares of ABIOMED (NASDAQ:ABMD) traded down $0.93 on Friday, reaching $252.20. 170,729 shares of the company were exchanged, compared to its average volume of 318,644. ABIOMED has a twelve month low of $103.82 and a twelve month high of $255.42. The firm has a market cap of $10,390.79 and a price-to-earnings ratio of 123.41. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.20 and a current ratio of 5.84.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.20. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The firm had revenue of $154.00 million during the quarter, compared to the consensus estimate of $154.00 million. During the same quarter in the previous year, the firm posted $0.34 EPS. The business’s revenue for the quarter was up 34.9% compared to the same quarter last year. analysts anticipate that ABIOMED will post 2.41 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABMD. Crow Point Partners LLC bought a new position in shares of ABIOMED during the fourth quarter valued at about $120,000. Cerebellum GP LLC bought a new position in shares of ABIOMED during the fourth quarter valued at about $127,000. Rehmann Capital Advisory Group bought a new position in shares of ABIOMED during the third quarter valued at about $202,000. Sigma Planning Corp bought a new position in shares of ABIOMED during the third quarter valued at about $206,000. Finally, Advisor Partners LLC bought a new position in shares of ABIOMED during the fourth quarter valued at about $209,000. 90.48% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Market News and is the sole property of of American Market News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/02/abiomed-abmd-price-target-increased-to-300-00-by-analysts-at-leerink-swann.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.